30-Oct-2026 22:07:17
CHEMKART INDIA H1 FY27: REVENUE SURGES 99% YOY; PAT UP 122%, NEW SEZ MANUFACTURING FACILITY TARGETED FOR FY27 & 60% MANUFACTURING REVENUE BY 2030
• FY30 Growth Target: Management aims to become India's No. 1 nutraceutical-focused CRDMO player by 2030, targeting 60% revenue contribution from manufacturing • FY27 Manufacturing Expansion: Plans to commission the greenfield EZRM nutraceutical manufacturing facility at JNPA SEZ, Maharashtra, during 2027 • Project Construction: Civil and structural work underway, including RCC construction and warehouse development, with 55 personnel deployed on-site • New Manufacturing Capabilities: Facility will focus on nutraceutical formulations, tablets, capsules, sachets, packaging and export-oriented contract manufacturing • FY27 R&D Plans: Plans to establish an R&D Innovation Centre and scale advanced technologies such as liposomal delivery, microencapsulation, nanoemulsions and beadlets • FY28 Expansion Plans: Targets entry into integrated manufacturing of bioactive molecules and establishment of overseas offices in the USA, Europe and Middle East • FY29 Business Strategy: Plans to offer full-service CDMO solutions, covering customised molecules through finished dosage forms • H1 Financial Results: Revenue surged 99.4% YoY to ₹205.87 Cr, EBITDA increased 107.5% to ₹29.37 Cr and PAT jumped 122.2% to ₹22.56 Cr • Half-Year Sequential Growth: Revenue increased 84.5%, EBITDA grew 109.5% and PAT surged 137.4% compared with H2 FY26 • Margin Improvement: EBITDA margin expanded to 14.3% from 13.7% YoY and 12.6% in H2 FY26 • Product Portfolio: Amino acids contributed 50% of H1 revenue, followed by sports nutrition at 28.8% and proteins at 8.4% • Export Expansion: Exports currently contribute 0.39% of revenue, with the new SEZ manufacturing facility aimed primarily at international markets • Capex Progress: Capital work-in-progress increased to ₹9.57 Cr from ₹4.87 Cr in March 2026, reflecting ongoing project investment • Cash Flow: H1 operating cash outflow stood at ₹18.71 Cr, while trade receivables increased to ₹89.50 Cr from ₹49.98 Cr in March 2026 • Future Growth Plans: Focused on shifting from ingredient distribution to higher-value manufacturing, expanding global customers, product innovation and improving margins through vertical integration • FY27 Guidance: Management highlighted healthy H2 business visibility and a strong sales pipeline but did not disclose specific FY27 revenue growth, margin or total project capex guidance
Chemkart India Limited